Vanda Pharmaceuticals (VNDA) Free Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.89% |
| Dec 31, 2025 | -29.27% |
| Sep 30, 2025 | -40.54% |
| Jun 30, 2025 | -21.55% |
| Mar 31, 2025 | -92.21% |
| Dec 31, 2024 | -17.17% |
| Sep 30, 2024 | -35.60% |
| Jun 30, 2024 | -18.61% |
| Mar 31, 2024 | -3.95% |
| Dec 31, 2023 | -17.73% |
| Sep 30, 2023 | -17.53% |
| Jun 30, 2023 | -38.39% |
| Mar 31, 2023 | 84.06% |
| Dec 31, 2022 | 22.82% |
| Sep 30, 2022 | 47.83% |
| Jun 30, 2022 | 31.31% |
| Mar 31, 2022 | 21.80% |
| Dec 31, 2021 | 74.29% |
| Sep 30, 2021 | 71.07% |
| Jun 30, 2021 | 50.57% |
| Mar 31, 2021 | 30.95% |
| Dec 31, 2020 | 80.46% |
| Sep 30, 2020 | 29.16% |
| Jun 30, 2020 | 14.78% |
| Mar 31, 2020 | -17.80% |
| Dec 31, 2019 | 22.05% |
| Sep 30, 2019 | 22.38% |
| Jun 30, 2019 | 20.58% |
| Mar 31, 2019 | 18.98% |
| Dec 31, 2018 | 26.54% |
| Sep 30, 2018 | 23.15% |
| Jun 30, 2018 | 20.43% |
| Mar 31, 2018 | 16.70% |
| Dec 31, 2017 | 17.46% |
| Sep 30, 2017 | 16.83% |
| Jun 30, 2017 | 25.26% |
| Mar 31, 2017 | 11.15% |
| Dec 31, 2016 | 31.47% |
| Sep 30, 2016 | 15.88% |
| Jun 30, 2016 | 10.31% |
| Mar 31, 2016 | -8.46% |
| Dec 31, 2015 | 26.81% |
| Sep 30, 2015 | -2.44% |